ASX - By Stock
|
IPD |
Re:
Ann: Notification of Results Release Dates and Conference Call
|
|
rlj
|
31 |
8.1K |
5 |
31/01/24 |
31/01/24 |
ASX - By Stock
|
31
|
8.1K
|
5
|
|
ASX - By Stock
|
1AD |
Re:
Ann: New malaria inhibiting i-body
|
|
rlj
|
62 |
18K |
5 |
17/01/24 |
17/01/24 |
ASX - By Stock
|
62
|
18K
|
5
|
|
ASX - By Stock
|
IPD |
Re:
Q2 predictions?
|
|
rlj
|
55 |
19K |
3 |
15/01/24 |
15/01/24 |
ASX - By Stock
|
55
|
19K
|
3
|
|
ASX - By Stock
|
IPD |
Re:
Q2 predictions?
|
|
rlj
|
55 |
19K |
3 |
14/01/24 |
14/01/24 |
ASX - By Stock
|
55
|
19K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: New malaria inhibiting i-body
|
|
rlj
|
62 |
18K |
0 |
21/12/23 |
21/12/23 |
ASX - By Stock
|
62
|
18K
|
0
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Atlantic Lithium Corporate Presentation December 2023
|
|
rlj
|
4 |
1.4K |
4 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
4
|
1.4K
|
4
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Atlantic Lithium Corporate Presentation December 2023
|
|
rlj
|
4 |
1.4K |
2 |
20/12/23 |
20/12/23 |
ASX - By Stock
|
4
|
1.4K
|
2
|
|
ASX - By Stock
|
1AD |
Re:
Ann: New malaria inhibiting i-body
|
|
rlj
|
62 |
18K |
4 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
62
|
18K
|
4
|
|
ASX - By Stock
|
IPD |
Re:
Media
|
|
rlj
|
322 |
117K |
3 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
322
|
117K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: New malaria inhibiting i-body
|
|
rlj
|
62 |
18K |
10 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
62
|
18K
|
10
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Trading Halt
|
|
rlj
|
9 |
2.5K |
2 |
15/12/23 |
15/12/23 |
ASX - By Stock
|
9
|
2.5K
|
2
|
|
ASX - By Stock
|
S32 |
Re:
general
|
|
rlj
|
171 |
97K |
2 |
28/11/23 |
28/11/23 |
ASX - By Stock
|
171
|
97K
|
2
|
|
ASX - By Stock
|
AMM |
Re:
Ann: AMM to Acquire Lithium Exploration Projects in Brazil
|
|
rlj
|
8 |
4.9K |
1 |
24/11/23 |
24/11/23 |
ASX - By Stock
|
8
|
4.9K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Security Class Suspension from Quotation PARO
|
|
rlj
|
10 |
4.4K |
1 |
21/11/23 |
21/11/23 |
ASX - By Stock
|
10
|
4.4K
|
1
|
|
ASX - By Stock
|
IPD |
Re:
Ann: ImpediMed announces leadership and Board changes
|
|
rlj
|
85 |
27K |
8 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
85
|
27K
|
8
|
|
ASX - By Stock
|
IPD |
Re:
Ann: ImpediMed announces leadership and Board changes
|
|
rlj
|
85 |
27K |
4 |
20/11/23 |
20/11/23 |
ASX - By Stock
|
85
|
27K
|
4
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Rejection of Non-Binding Indicative Offers from Assore
|
|
rlj
|
27 |
10K |
2 |
15/11/23 |
15/11/23 |
ASX - By Stock
|
27
|
10K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
rlj
|
26 |
9.2K |
3 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
26
|
9.2K
|
3
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Promising Clinical Data 1b ACCENT Trial in Pancreatic Cancer
|
|
rlj
|
26 |
9.2K |
2 |
06/11/23 |
06/11/23 |
ASX - By Stock
|
26
|
9.2K
|
2
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Largest US Private Payor Updates Medical Policy for BIS
|
|
rlj
|
41 |
13K |
3 |
03/11/23 |
03/11/23 |
ASX - By Stock
|
41
|
13K
|
3
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Appendix 4C & Quarterly Activities Report - Sep-23 Qtr
|
|
rlj
|
89 |
24K |
2 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
89
|
24K
|
2
|
|
ASX - By Stock
|
IPD |
Re:
Ann: APPENDIX 4C - Quarterly Activities Report
|
|
rlj
|
54 |
18K |
0 |
01/11/23 |
01/11/23 |
ASX - By Stock
|
54
|
18K
|
0
|
|
ASX - By Stock
|
IMU |
Re:
Ann: Notice of Annual General Meeting/Proxy Form
|
|
rlj
|
324 |
106K |
22 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
324
|
106K
|
22
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Notice of General Meeting/Proxy Form
|
|
rlj
|
3 |
1.0K |
4 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
3
|
1.0K
|
4
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Appendix 4C & Quarterly Activities Report - Sep-23 Qtr
|
|
rlj
|
89 |
24K |
2 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
89
|
24K
|
2
|
|
ASX - By Stock
|
ATX |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
rlj
|
1 |
962 |
2 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
1
|
962
|
2
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Quarterly Results and Investor Conference Call
|
|
rlj
|
8 |
3.2K |
1 |
31/10/23 |
31/10/23 |
ASX - By Stock
|
8
|
3.2K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Fin Rev- Paradigm looking to raise funds
|
|
rlj
|
101 |
30K |
2 |
29/10/23 |
29/10/23 |
ASX - By Stock
|
101
|
30K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Fin Rev- Paradigm looking to raise funds
|
|
rlj
|
101 |
30K |
7 |
29/10/23 |
29/10/23 |
ASX - By Stock
|
101
|
30K
|
7
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Quarterly Results and Investor Conference Call
|
|
rlj
|
8 |
3.2K |
4 |
26/10/23 |
26/10/23 |
ASX - By Stock
|
8
|
3.2K
|
4
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Quarterly Results and Investor Conference Call
|
|
rlj
|
8 |
3.2K |
3 |
24/10/23 |
24/10/23 |
ASX - By Stock
|
8
|
3.2K
|
3
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Dosing simulations support AD-214 IV product profile
|
|
rlj
|
12 |
3.8K |
1 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
12
|
3.8K
|
1
|
|
ASX - By Stock
|
NVA |
Re:
Ann: Additional Highly Prospective Claims Staked at Estelle
|
|
rlj
|
34 |
9.8K |
1 |
06/10/23 |
06/10/23 |
ASX - By Stock
|
34
|
9.8K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Dosing simulations support AD-214 IV product profile
|
|
rlj
|
12 |
3.8K |
1 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
12
|
3.8K
|
1
|
|
ASX - By Stock
|
1AD |
Re:
Ann: Dosing simulations support AD-214 IV product profile
|
|
rlj
|
12 |
3.8K |
0 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
12
|
3.8K
|
0
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Initial Director's Interest Notice - Ms Janelle Delaney
|
|
rlj
|
22 |
5.5K |
2 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
22
|
5.5K
|
2
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Initial Director's Interest Notice - Ms Janelle Delaney
|
|
rlj
|
22 |
5.5K |
1 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
22
|
5.5K
|
1
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Initial Director's Interest Notice - Ms Janelle Delaney
|
|
rlj
|
22 |
5.5K |
6 |
04/10/23 |
04/10/23 |
ASX - By Stock
|
22
|
5.5K
|
6
|
|
ASX - By Stock
|
OZM |
Re:
Ann: OzAurum Acquires Lithium Project in Brazil
|
|
rlj
|
373 |
84K |
17 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
373
|
84K
|
17
|
|
ASX - By Stock
|
OZM |
Re:
Ann: OzAurum Acquires Lithium Project in Brazil
|
|
rlj
|
373 |
84K |
4 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
373
|
84K
|
4
|
|
ASX - By Stock
|
LLL |
Re:
Ann: Suspension from Quotation
|
|
rlj
|
479 |
176K |
4 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
479
|
176K
|
4
|
|
ASX - By Stock
|
LLL |
Re:
Ann: Suspension from Quotation
|
|
rlj
|
479 |
176K |
24 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
479
|
176K
|
24
|
|
ASX - By Stock
|
LLL |
Re:
Ann: Suspension from Quotation
|
|
rlj
|
479 |
176K |
6 |
19/09/23 |
19/09/23 |
ASX - By Stock
|
479
|
176K
|
6
|
|
ASX - By Stock
|
OZM |
Re:
Ann: OzAurum Acquires Lithium Project in Brazil
|
|
rlj
|
373 |
84K |
9 |
15/09/23 |
15/09/23 |
ASX - By Stock
|
373
|
84K
|
9
|
|
ASX - By Stock
|
IPD |
Re:
Acaidia Park Responce
|
|
rlj
|
41 |
11K |
7 |
13/09/23 |
13/09/23 |
ASX - By Stock
|
41
|
11K
|
7
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Minerals Income Investment Fund of Ghana Invests US$32.9m
|
|
rlj
|
69 |
17K |
10 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
69
|
17K
|
10
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Minerals Income Investment Fund of Ghana Invests US$32.9m
|
|
rlj
|
69 |
17K |
6 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
69
|
17K
|
6
|
|
ASX - By Stock
|
A11 |
Re:
Ann: Minerals Income Investment Fund of Ghana Invests US$32.9m
|
|
rlj
|
69 |
17K |
6 |
08/09/23 |
08/09/23 |
ASX - By Stock
|
69
|
17K
|
6
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Shareholder Update on Section 249D Notice & Company Position
|
|
rlj
|
101 |
28K |
3 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
101
|
28K
|
3
|
|
ASX - By Stock
|
IPD |
Re:
Ann: Shareholder Update on Section 249D Notice & Company Position
|
|
rlj
|
101 |
28K |
6 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
101
|
28K
|
6
|
|